This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
PRRT with somatostatin analogs shows disease control rates up to 80% in lung carcinoids, paragangliomas, and meningiomas, but only 177Lu-DOTATATE is approved (for GEP-NETs). Combination and alpha-emitter therapies are emerging.
Why it matters
Many cancers beyond gut neuroendocrine tumors express somatostatin receptors. Expanding PRRT approvals could help patients with limited treatment options.
The numbers in context
177Lu-DOTATATE approved for GEP-NETs; disease control up to 80% in lung carcinoids, paragangliomas, meningiomas; SST discovered 1972; 5 SSTR subtypes; combination and alpha-emitter therapies emerging
How the study worked
Narrative review of PRRT applications beyond GEP-NETs, covering efficacy data from retrospective studies, emerging combination strategies, and alpha-emitter therapy.
Who was studied
N/A (review of PRRT in SSTR-expressing cancers beyond GEP-NETs)
What this study cannot tell us
Narrative format. Most evidence is from small retrospective studies. No randomized trials for non-GEP-NET indications. Patient selection criteria not standardized across tumor types.
Read the original research
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.
Journal of neuroendocrinology, 37(3), e70013
Citation
Santo, Giulia; di Santo, Gianpaolo; Cicone, Francesco; Virgolini, Irene. (2025). Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.. Journal of neuroendocrinology, 37(3), e70013. https://doi.org/10.1111/jne.70013